{"id":"https://openalex.org/W2809716709","doi":"https://doi.org/10.1080/13543784.2018.1494153","title":"MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis","display_name":"MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis","alternate_titles":[],"publication_year":2018,"publication_date":"2018-07-03","ids":{"openalex":"https://openalex.org/W2809716709","doi":"https://doi.org/10.1080/13543784.2018.1494153","mag":"2809716709","pmid":"https://pubmed.ncbi.nlm.nih.gov/29950116"},"language":"en","primary_location":{"id":"doi:10.1080/13543784.2018.1494153","doi":"https://doi.org/10.1080/13543784.2018.1494153","is_oa":false,"landing_page_url":"https://doi.org/10.1080/13543784.2018.1494153","pdf_url":null,"source":{"id":"https://openalex.org/S131064935","display_name":"Expert Opinion on Investigational Drugs","issn_l":"1354-3784","issn":["1354-3784","1744-7658"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Investigational Drugs","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2809716709"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5066051920","display_name":"Jerry R. Colca","orcid":"https://orcid.org/0000-0003-3933-8626","observed_orcids":["https://orcid.org/0000-0003-3933-8626"]},"institutions":[],"countries":[],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Jerry R. Colca","raw_affiliation_strings":["Cirius Therapeutics, Kalamazoo, MI, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cirius Therapeutics, Kalamazoo, MI, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"William G McDonald","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115899","display_name":"Metabolic Solutions Development Company (United States)","ror":"https://ror.org/0295q2p17","country_code":"US","type":"company","lineage":["https://openalex.org/I4210115899"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"William G McDonald","raw_affiliation_strings":["Metabolic Solutions Development Company (MSDC), Kalamazoo, MI, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Metabolic Solutions Development Company (MSDC), Kalamazoo, MI, USA","institution_ids":["https://openalex.org/I4210115899"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5044676290","display_name":"Wade J. Adams","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Wade J. Adams","raw_affiliation_strings":["Cirius Therapeutics, Kalamazoo, MI, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cirius Therapeutics, Kalamazoo, MI, USA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5066051920"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.6729,"has_fulltext":false,"cited_by_count":50,"citation_normalized_percentile":{"value":0.63812155,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":92,"max":99},"biblio":{"volume":"27","issue":"7","first_page":"631","last_page":"636"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10351","display_name":"Liver Disease Diagnosis and Treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10351","display_name":"Liver Disease Diagnosis and Treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11465","display_name":"Drug-Induced Hepatotoxicity and Protection","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11207","display_name":"Alcohol Consumption and Health Effects","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/non-alcoholic-steatohepatitis","display_name":"nonalcoholic steatohepatitis","score":0.9950000047683716},{"id":"https://openalex.org/keywords/non-alcoholic-fatty-liver-disease","display_name":"non-alcoholic fatty liver disease","score":0.972000002861023},{"id":"https://openalex.org/keywords/mitochondrial-pyruvate-carrier","display_name":"mitochondrial pyruvate carrier","score":0.996999979019165},{"id":"https://openalex.org/keywords/metabolic-regulators","display_name":"metabolic modulators","score":0.7670000195503235},{"id":"https://openalex.org/keywords/lipid-metabolism","display_name":"lipid metabolism","score":0.7139999866485596},{"id":"https://openalex.org/keywords/insulin-resistance","display_name":"insulin resistance","score":0.8270000219345093},{"id":"https://openalex.org/keywords/liver-fibrosis","display_name":"liver fibrosis","score":0.7720000147819519},{"id":"https://openalex.org/keywords/inflammation","display_name":"inflammation","score":0.7059999704360962}],"concepts":[{"id":"https://openalex.org/C2779478299","wikidata":"https://www.wikidata.org/wiki/Q2335423","display_name":"Steatohepatitis","level":4,"score":0.9407225847244263},{"id":"https://openalex.org/C2778772119","wikidata":"https://www.wikidata.org/wiki/Q6058862","display_name":"Fatty liver","level":3,"score":0.8113994598388672},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5291327238082886},{"id":"https://openalex.org/C2777391703","wikidata":"https://www.wikidata.org/wiki/Q1053470","display_name":"Insulin resistance","level":3,"score":0.47794249653816223},{"id":"https://openalex.org/C60644358","wikidata":"https://www.wikidata.org/wiki/Q128570","display_name":"Bioinformatics","level":1,"score":0.42914408445358276},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.3333033621311188},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.27458706498146057},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2730012536048889},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.2069735825061798}],"mesh":[{"descriptor_ui":"D000098","descriptor_name":"Acetophenones","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007249","descriptor_name":"Inflammation","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D007249","descriptor_name":"Inflammation","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D007333","descriptor_name":"Insulin Resistance","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008103","descriptor_name":"Liver Cirrhosis","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D008103","descriptor_name":"Liver Cirrhosis","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D045162","descriptor_name":"Thiazolidinediones","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D050356","descriptor_name":"Lipid Metabolism","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D065626","descriptor_name":"Non-alcoholic Fatty Liver Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D065626","descriptor_name":"Non-alcoholic Fatty Liver Disease","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1080/13543784.2018.1494153","doi":"https://doi.org/10.1080/13543784.2018.1494153","is_oa":false,"landing_page_url":"https://doi.org/10.1080/13543784.2018.1494153","pdf_url":null,"source":{"id":"https://openalex.org/S131064935","display_name":"Expert Opinion on Investigational Drugs","issn_l":"1354-3784","issn":["1354-3784","1744-7658"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Investigational Drugs","raw_type":"journal-article"},{"id":"pmid:29950116","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/29950116","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert opinion on investigational drugs","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":35,"referenced_works":["https://openalex.org/W37971782","https://openalex.org/W90736706","https://openalex.org/W1981961082","https://openalex.org/W1985538633","https://openalex.org/W1998383277","https://openalex.org/W2013334588","https://openalex.org/W2054277796","https://openalex.org/W2067945714","https://openalex.org/W2070520886","https://openalex.org/W2094229041","https://openalex.org/W2102186262","https://openalex.org/W2103135709","https://openalex.org/W2127403426","https://openalex.org/W2128009079","https://openalex.org/W2129164045","https://openalex.org/W2165311378","https://openalex.org/W2204688218","https://openalex.org/W2251528817","https://openalex.org/W2259003342","https://openalex.org/W2265176083","https://openalex.org/W2291276541","https://openalex.org/W2326389904","https://openalex.org/W2404306813","https://openalex.org/W2470709274","https://openalex.org/W2521245051","https://openalex.org/W2522715783","https://openalex.org/W2531626219","https://openalex.org/W2563249905","https://openalex.org/W2593506275","https://openalex.org/W2606429878","https://openalex.org/W2744389809","https://openalex.org/W2752428556","https://openalex.org/W2760183031","https://openalex.org/W2767673297","https://openalex.org/W2774672890"],"related_works":["https://openalex.org/W2795880183","https://openalex.org/W2563249905","https://openalex.org/W2986883158","https://openalex.org/W3176964000","https://openalex.org/W2948711638","https://openalex.org/W2895834165","https://openalex.org/W2601448796","https://openalex.org/W4317358649","https://openalex.org/W3047623858","https://openalex.org/W4282586600"],"abstract_inverted_index":{"INTRODUCTION:":[0],"Non-alcoholic":[1],"steatohepatitis":[2],"(NASH)":[3],"is":[4,17,22,51,94],"a":[5,40,55,147],"serious":[6],"form":[7],"of":[8,27,42,53,70,100,105,116,118,126,154],"non-alcoholic":[9],"fatty":[10,71],"liver":[11,72,86],"disease":[12],"(NAFLD)":[13],"for":[14,124,151],"which":[15],"there":[16],"no":[18],"marketed":[19],"treatments.":[20],"NAFLD":[21],"initiated":[23],"by":[24],"excess":[25],"intake":[26],"nutrients":[28],"and":[29,64,78,103],"recent":[30],"evidence":[31],"has":[32,142],"pinpointed":[33],"the":[34,43,62,68,84,97,101,127,143,152],"mitochondrial":[35],"pyruvate":[36],"carrier":[37],"(MPC)":[38],"as":[39,65,81,83],"mediator":[41],"nutritional":[44],"overload":[45],"signals.":[46],"Areas":[47],"covered:":[48],"An":[49,130],"overview":[50],"given":[52],"MSDC-0602K,":[54],"new":[56],"agent":[57],"in":[58],"development":[59],"that":[60],"modulates":[61],"MPC":[63],"such":[66],"treats":[67],"symptoms":[69],"including":[73,88],"dysfunctional":[74],"lipid":[75],"metabolism,":[76],"inflammation,":[77],"insulin":[79],"resistance":[80],"well":[82],"key":[85],"pathology":[87],"fibrosis.":[89],"METHODOLOGY:":[90],"The":[91,114],"current":[92],"evaluation":[93],"written":[95],"from":[96],"direct":[98],"experience":[99],"authors":[102],"review":[104],"published":[106],"literature":[107],"using":[108],"standard":[109],"search":[110],"techniques.":[111],"Expert":[112],"Opinion:":[113],"mechanism":[115],"action":[117],"MSDC-0602K":[119,141],"appears":[120],"to":[121,145],"be":[122,146],"suited":[123],"treatment":[125,153],"NASH":[128],"pathophysiology.":[129],"ongoing":[131],"phase":[132],"2b":[133],"dose-ranging":[134],"trial":[135],"should":[136],"demonstrate":[137],"whether":[138],"or":[139],"not":[140],"potential":[144],"cornerstone":[148],"metabolic":[149],"therapy":[150],"NASH.":[155]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2809716709","counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":6},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":10},{"year":2021,"cited_by_count":7},{"year":2020,"cited_by_count":9},{"year":2019,"cited_by_count":6},{"year":2018,"cited_by_count":2}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2018-07-10T00:00:00"}
